Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Non-Current Deffered Revenue: 2024

Historic Non-Current Deffered Revenue for Kura Oncology (KURA) over the last 1 years, with Dec 2024 value amounting to $253.9 million.

  • Kura Oncology's Non-Current Deffered Revenue was N/A to $268.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $268.9 million, marking a year-over-year change of. This contributed to the annual value of $253.9 million for FY2024, which is N/A change from last year.
  • According to the latest figures from FY2024, Kura Oncology's Non-Current Deffered Revenue is $253.9 million.
  • Over the past 5 years, Kura Oncology's Non-Current Deffered Revenue peaked at $253.9 million during FY2024, and registered a low of $253.9 million during FY2024.
  • Its 1-year average for Non-Current Deffered Revenue is $253.9 million, with a median of $253.9 million in 2024.